An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy

An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy

Immune-checkpoint inhibitors (ICIs) have an established role in the treatment of locally advanced and metastatic non-small cell lung cancer (NSCLC). ICIs have now entered the paradigm of early-stage NSCLC. The recent evidence shows that the addition of ICI to neoadjuvant chemotherapy improves the pa...

Full description

Bibliographic Details
Main Authors: Saurav Verma, Daniel Breadner, Abhenil Mittal, David A. Palma, Rahul Nayak, Jacques Raphael, Mark Vincent
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Cancers
Subjects:
stage III
resectable
locally advanced
NSCLC
lung cancer
immunotherapy
Online Access:https://www.mdpi.com/2072-6694/16/7/1302

Internet

https://www.mdpi.com/2072-6694/16/7/1302

Similar Items